美洲大蠊提取物CⅡ-3联合CTX对H22荷瘤小鼠的增效及减毒作用

IF 0.8 4区 医学 Q3 EDUCATION, SCIENTIFIC DISCIPLINES Indian Journal of Pharmaceutical Education and Research Pub Date : 2023-10-04 DOI:10.5530/ijper.57.4.135
Rui Yuan, Guangming Liu, Meixian Guo, Xiaobo Liu
{"title":"美洲大蠊提取物CⅡ-3联合CTX对H22荷瘤小鼠的增效及减毒作用","authors":"Rui Yuan, Guangming Liu, Meixian Guo, Xiaobo Liu","doi":"10.5530/ijper.57.4.135","DOIUrl":null,"url":null,"abstract":"Abstract: Background: Cyclophosphamide (CTX) is widely used in tumor treatment, but its clinical therapeutic effect is not ideal due to many side effects. Materials and Methods: In the present study, we researched the synergistic and attenuating effects of CⅡ-3 combined with CTX and their underlying mechanism in H22 tumor-bearing mice. Firstly, we established an H22 tumor-bearing mice model, and the body weight, tumor weight, and survival time were recorded. Secondly, HE staining of tumor tissue was performed, and the related organ index, NK cell killing activity, peripheral blood cells, and bone marrow nucleated cells were measured. Moreover, the changes in IL-6 and IFN-1β in serum were detected by ELISA. Finally, RT-qPCR and Western Blot were performed to detect the expressions of TLR4, TLR9 and NF-κB in tumor tissue. Results: The treatment of CⅡ-3 combined with CTX could increase life extension rate of H22 tumor-bearing mice, reduce tumor weight. Additionally, it could inhibit tumor cell proliferation, increase thymus and spleen index, enhance the activity of T cells in spleen, promote the killing activity of NK cells, and had a certain ameliorate effect on the reduction of WBC, Neut, LYM and bone marrow nucleated cells caused by CTX. And the expression of mRNA and the protein of TLR4, TLR9 and NF-κB in tumor mass of H22 tumor-bearing mice were down-regulated. Conclusion: There were synergistic and attenuating effects of CTX combined with CⅡ-3 in the treatment of tumor and the effects might be mediated by the TLR4/NF-κB and TLR9/NF-κB signaling pathways. Keywords Anti-tumor, Cyclophosphamide, Immune depression, Periplaneta americana, Synergism and attenuation.","PeriodicalId":13407,"journal":{"name":"Indian Journal of Pharmaceutical Education and Research","volume":"210 1","pages":"0"},"PeriodicalIF":0.8000,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synergistic and Toxicity-reducing Effects of Periplaneta americana Extract CⅡ-3 Combined with CTX on H22 Tumor Bearing Mice\",\"authors\":\"Rui Yuan, Guangming Liu, Meixian Guo, Xiaobo Liu\",\"doi\":\"10.5530/ijper.57.4.135\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract: Background: Cyclophosphamide (CTX) is widely used in tumor treatment, but its clinical therapeutic effect is not ideal due to many side effects. Materials and Methods: In the present study, we researched the synergistic and attenuating effects of CⅡ-3 combined with CTX and their underlying mechanism in H22 tumor-bearing mice. Firstly, we established an H22 tumor-bearing mice model, and the body weight, tumor weight, and survival time were recorded. Secondly, HE staining of tumor tissue was performed, and the related organ index, NK cell killing activity, peripheral blood cells, and bone marrow nucleated cells were measured. Moreover, the changes in IL-6 and IFN-1β in serum were detected by ELISA. Finally, RT-qPCR and Western Blot were performed to detect the expressions of TLR4, TLR9 and NF-κB in tumor tissue. Results: The treatment of CⅡ-3 combined with CTX could increase life extension rate of H22 tumor-bearing mice, reduce tumor weight. Additionally, it could inhibit tumor cell proliferation, increase thymus and spleen index, enhance the activity of T cells in spleen, promote the killing activity of NK cells, and had a certain ameliorate effect on the reduction of WBC, Neut, LYM and bone marrow nucleated cells caused by CTX. And the expression of mRNA and the protein of TLR4, TLR9 and NF-κB in tumor mass of H22 tumor-bearing mice were down-regulated. Conclusion: There were synergistic and attenuating effects of CTX combined with CⅡ-3 in the treatment of tumor and the effects might be mediated by the TLR4/NF-κB and TLR9/NF-κB signaling pathways. Keywords Anti-tumor, Cyclophosphamide, Immune depression, Periplaneta americana, Synergism and attenuation.\",\"PeriodicalId\":13407,\"journal\":{\"name\":\"Indian Journal of Pharmaceutical Education and Research\",\"volume\":\"210 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2023-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Pharmaceutical Education and Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5530/ijper.57.4.135\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"EDUCATION, SCIENTIFIC DISCIPLINES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Pharmaceutical Education and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5530/ijper.57.4.135","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"EDUCATION, SCIENTIFIC DISCIPLINES","Score":null,"Total":0}
引用次数: 0

摘要

摘要:背景:环磷酰胺(Cyclophosphamide, CTX)广泛应用于肿瘤治疗,但其副作用多,临床治疗效果不理想。材料与方法:本实验研究CⅡ-3联合CTX对H22荷瘤小鼠的增效、减毒作用及其机制。首先建立H22荷瘤小鼠模型,记录体重、肿瘤重量、生存时间。其次,对肿瘤组织进行HE染色,测定相关脏器指数、NK细胞杀伤活性、外周血细胞、骨髓有核细胞。ELISA法检测血清中IL-6、IFN-1β的变化。最后采用RT-qPCR和Western Blot检测肿瘤组织中TLR4、TLR9和NF-κB的表达。结果:CⅡ-3联合CTX治疗可提高H22荷瘤小鼠的寿命延长率,减轻肿瘤重量。抑制肿瘤细胞增殖,提高胸腺和脾脏指数,增强脾脏T细胞活性,促进NK细胞杀伤活性,对CTX所致WBC、Neut、LYM及骨髓有核细胞减少有一定改善作用。H22荷瘤小鼠肿瘤组织中TLR4、TLR9、NF-κB mRNA及蛋白表达下调。结论:CTX联合CⅡ-3治疗肿瘤具有增效和减毒作用,其作用可能通过TLR4/NF-κB和TLR9/NF-κB信号通路介导。关键词抗肿瘤,环磷酰胺,免疫抑制,美洲大蠊,协同衰减。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Synergistic and Toxicity-reducing Effects of Periplaneta americana Extract CⅡ-3 Combined with CTX on H22 Tumor Bearing Mice
Abstract: Background: Cyclophosphamide (CTX) is widely used in tumor treatment, but its clinical therapeutic effect is not ideal due to many side effects. Materials and Methods: In the present study, we researched the synergistic and attenuating effects of CⅡ-3 combined with CTX and their underlying mechanism in H22 tumor-bearing mice. Firstly, we established an H22 tumor-bearing mice model, and the body weight, tumor weight, and survival time were recorded. Secondly, HE staining of tumor tissue was performed, and the related organ index, NK cell killing activity, peripheral blood cells, and bone marrow nucleated cells were measured. Moreover, the changes in IL-6 and IFN-1β in serum were detected by ELISA. Finally, RT-qPCR and Western Blot were performed to detect the expressions of TLR4, TLR9 and NF-κB in tumor tissue. Results: The treatment of CⅡ-3 combined with CTX could increase life extension rate of H22 tumor-bearing mice, reduce tumor weight. Additionally, it could inhibit tumor cell proliferation, increase thymus and spleen index, enhance the activity of T cells in spleen, promote the killing activity of NK cells, and had a certain ameliorate effect on the reduction of WBC, Neut, LYM and bone marrow nucleated cells caused by CTX. And the expression of mRNA and the protein of TLR4, TLR9 and NF-κB in tumor mass of H22 tumor-bearing mice were down-regulated. Conclusion: There were synergistic and attenuating effects of CTX combined with CⅡ-3 in the treatment of tumor and the effects might be mediated by the TLR4/NF-κB and TLR9/NF-κB signaling pathways. Keywords Anti-tumor, Cyclophosphamide, Immune depression, Periplaneta americana, Synergism and attenuation.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.40
自引率
0.00%
发文量
227
审稿时长
>12 weeks
期刊介绍: The official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967. IJPER, a quarterly publication devoted to publish reviews and research articles in pharmacy and the related disciplines of Pharmaceutical education. It mainly covers the articles of special interest, covering the areas of Pharmaceutical research, teaching and learning, laboratory innovations, education technology, curriculum design, examination reforms, training and other related issues. It encourages debates and discussions on the issues of vital importance to Pharmaceutical education and research. The goal of the journal is to provide the quality publications and publish most important research and review articles in the field of drug development and pharmaceutical education. It is circulated and referred by more than 6000 teachers, 40,000 students and over 1000 professionals working in Pharmaceutical industries, Regulatory departments, hospitals etc.
期刊最新文献
A Novel Approach on Micro Sponges Drug Delivery System: Method of Preparations, Application, and its Future Prospective Evaluation of Utilization and Satisfaction of Patients towards Pharmaceutical Services in Hospitals: A Descriptive Study from Al-Jouf Region of Saudi Arabia A Case Report of Retracted Publications in Pharmaceutical Science as a Remedy for Research Malpractice Histopathological Changes in Animal Models by Catheters Coated with Saudi Medicinal Herb Evolvulus alsinoides L. Extract in Urinary Tract Infections by Klebsiella pneumoniae Assessment of the Quality of Education Received by Undergraduate Pharmacy Students in Selected Universities in Nigeria
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1